| Summarized segment financial information |
| Three Months Ended September 30, 2018 |
| |
ADMA BioManufacturing |
|
Plasma Collection Centers |
|
Corporate |
|
Consolidated |
| |
|
|
|
|
|
|
|
| Revenues |
$ 1,985,630 |
|
$ 2,208,972 |
|
$ 35,708 |
|
$ 4,230,310 |
| |
|
|
|
|
|
|
|
| Cost of product revenue |
7,671,279 |
|
1,492,830 |
|
- |
|
9,164,109 |
| |
|
|
|
|
|
|
|
| Loss from operations |
(10,214,933) |
|
(1,257,196) |
|
(2,319,271) |
|
(13,791,400) |
| |
|
|
|
|
|
|
|
| Interest and other expense, net |
(255,410) |
|
849 |
|
(1,089,524) |
|
(1,344,085) |
| |
|
|
|
|
|
|
|
| Net loss |
(10,470,343) |
|
(1,256,347) |
|
(3,408,795) |
|
(15,135,485) |
| |
|
|
|
|
|
|
|
| Total assets |
56,123,178 |
|
5,524,105 |
|
44,697,817 |
|
106,345,100 |
| |
|
|
|
|
|
|
|
| Depreciation and amortization expense |
651,317 |
|
191,547 |
|
4,193 |
|
847,057 |
| Nine Months Ended September 30, 2018 |
| |
ADMA BioManufacturing |
|
Plasma Collection Centers |
|
Corporate |
|
Consolidated |
| |
|
|
|
|
|
|
|
| Revenues |
$ 5,796,597 |
|
$ 7,025,144 |
|
$ 107,125 |
|
$ 12,928,866 |
| |
|
|
|
|
|
|
|
| Cost of product revenue |
26,334,602 |
|
4,717,917 |
|
- |
|
31,052,519 |
| |
|
|
|
|
|
|
|
| Loss from operations |
(32,656,560) |
|
(3,238,013) |
|
(7,846,711) |
|
(43,741,284) |
| |
|
|
|
|
|
|
|
| Interest and other expense, net |
(732,623) |
|
(22) |
|
(3,231,529) |
|
(3,964,174) |
| |
|
|
|
|
|
|
|
| Net loss |
(33,389,183) |
|
(3,238,035) |
|
(11,078,240) |
|
(47,705,458) |
| |
|
|
|
|
|
|
|
| Capital expenditures |
772,339 |
|
504,255 |
|
- |
|
1,276,594 |
| |
|
|
|
|
|
|
|
| Depreciation and amortization expense |
1,922,448 |
|
581,059 |
|
18,989 |
|
2,522,496 |
| Three Months Ended September 30, 2017 |
| |
ADMA BioManufacturing |
|
Plasma Collection Centers |
|
Corporate |
|
Consolidated |
| |
|
|
|
|
|
|
|
| Revenues |
$ 1,879,921 |
|
$ 2,813,782 |
|
$ 35,708 |
|
$ 4,729,411 |
| |
|
|
|
|
|
|
|
| Cost of product revenue |
9,552,128 |
|
1,738,988 |
|
- |
|
11,291,116 |
| |
|
|
|
|
|
|
|
| Loss from operations |
(10,532,500) |
|
(507,900) |
|
(3,387,360) |
|
(14,427,760) |
| |
|
|
|
|
|
|
|
| Interest and other expense, net |
(237,548) |
|
- |
|
(537,407) |
|
(774,955) |
| |
|
|
|
|
|
|
|
| Net loss |
(10,770,048) |
|
(507,900) |
|
(3,924,767) |
|
(15,202,715) |
| |
|
|
|
|
|
|
|
| Total assets |
55,452,496 |
|
3,517,274 |
|
13,843,710 |
|
72,813,480 |
| |
|
|
|
|
|
|
|
| Depreciation and amortization expense |
723,098 |
|
102,263 |
|
10,710 |
|
836,071 |
| Nine Months Ended September 30, 2017 |
| |
ADMA BioManufacturing |
|
Plasma Collection Centers |
|
Corporate |
|
Consolidated |
| |
|
|
|
|
|
|
|
| Revenues |
$ 2,419,144 |
|
$ 8,231,414 |
|
$ 107,125 |
|
$ 10,757,683 |
| |
|
|
|
|
|
|
|
| Cost of product revenue |
12,050,984 |
|
5,190,438 |
|
- |
|
17,241,422 |
| |
|
|
|
|
|
|
|
| Loss from operations |
(13,650,801) |
|
(1,621,364) |
|
(13,494,466) |
|
(28,766,631) |
| |
|
|
|
|
|
|
|
| Interest and other expense, net |
(299,535) |
|
- |
|
(1,710,007) |
|
(2,009,542) |
| |
|
|
|
|
|
|
|
| Net loss |
(13,950,336) |
|
(1,621,364) |
|
(15,204,473) |
|
(30,776,173) |
| |
|
|
|
|
|
|
|
| Depreciation and amortization expense |
881,496 |
|
309,606 |
|
40,163 |
|
1,231,265 |
| |
|
|
|
|
|
|
|
| Capital expenditures |
360,000 |
|
291,194 |
|
15,263 |
|
666,457 |
|